Patent GB-1094773-A (GB)
Title: 5-nitroimidazole derivatives
IPC: C07D233/95
Filed: 1965-02-08
Abstract: Novel 5-nitroimidazoles of the Formulae I and II <FORM:1094773/C2/1> in which R is a C1- 5 alkyl or -(CH2)nOY radical where n is 2, 3 or 4 and Y is H or an acyl radical -NR2R3 is an amino, alkylamino, dialkylamino, alkenylamino, arylamino, aralkylamino amino (in which the aryl residue may be a heterocyclic aromatic group and may bear substituents), cycloalkylamino, C1- 6 alkanoylamino or benzoylamino radical a urea residue or an N-containing 5-membered or non-aromatic 6-membered heterocyclic ring, e.g. a morpholine, thiamorpholine, piperidine, pyrrolidine, piperazine, imidazoline, triazoline, pyrrole, pyrazole, pyrrolidone, piperidone, pyrazolone or imidazolone radical, A is C1- 5 alkyl and R1 is C1- 5 alkyl are made as follows: (a) in the case where NR2R3 is an alkylamino, dialkylamino, alkenylamino, arylamino or cycloalkylamino radical or a heterocyclic ring, by reacting a 2-halomethyl 5-nitroimidazole with an amine of the formula HNR2R3; (b) in the case where NR2R3 is an amino group, by reacting the appropriate 1-substituted-2-halomethyl-5-nitroimidazole with an alkali-metal phthalimide and treating the resulting phthalimidomethyl-5-nitroimidazole with hydrazine; (c) in the case where NR2R3 is an aralkylamino residue, by dehydrating a 1-(C1- 5 alkyl)-2-(a -hydroxy-a -arylalkylamino) - methyl - 5 - nitroimidazole by the action of silica gel and reducing the resulting aralkylimino-compound with an alkali-metalborohydride and (d) in the case where NR2R3 is an acylamino radical, by nitrating a 2-acylaminomethylimidazole and alkylating the resulting 2-acylaminomethyl-5-nitroimidazole to introduce the 1-substituent. 2-Acetamidomethylimidazole is made by reacting 1 - benzyl - 2 - hydroxymethylimidazole with thionyl chloride, treating the resulting 1 - benzyl - 2 - chloromethylimidazole with ammonia to give 1-benzyl-2-aminomethylimidazole, removing the benzyl group by reaction with sodium in liquid ammonia and acetylating with acetic anhydride.  1 - Methyl - 2 - benzyliminomethyl - 5 - nitroimidazole is made by oxidizing 1-methyl-2-hydroxymethyl - 5 - nitroimidazole with MnO2 to 1 - methyl - 2 - formyl - 5 - nitroimidazole, reacting with benzylamine to give 1-methyl-2-(a  - hydroxy - a  - benzylamino - methyl) - 5 - nitroimidazole and dehydrating with silica gel.  1 - Alkyl - 2 - hydroxymethyl - 5 - nitroimidazoles are made by acetylating 2-hydroxymethyl imidazole with acetic anhydride, nitrating the resulting 2-acetoxymethyl imidazole and hydrolysing to give 2-hydroxymethyl-4-nitroimidazole and alkylating, e.g. with dimethyl-, diethyl- or dipropyl-sulphate.  1 - Alkyl - 2 - a  - hydroxyalkyl - 5 - nitroimidazoles are made by reacting 1,2-dimethyl-5-nitroimidazole with benzaldehyde to give 1 - methyl - 2 - (b  - phenylvinyl) - 5 - nitroimiazole oxidizing with sodium periodate and osmium tetroxide to 1-methyl-2-formyl - 5 - nitroimidazole and reacting with methyl magnesium iodide. Pharmaceutical and veterinary preparations for treatment of parasitic infections such as histomoniasis and trichomoniasis comprise the above compounds of the invention and a carrier. Suitable preparations include tablets, capsules, solutions, suspensions and foodstuff additives for oral treatment of enterohepatitis in turkeys and suppositories, or creams for topical treatment of human vaginitis.